Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion - "Nadir+2"?

被引:44
作者
Nielsen, Matthew E. [1 ]
Makarov, Danil V. [1 ]
Humphreys, Elizabeth [1 ]
Mangold, Leslie [1 ]
Partin, Alan W. [1 ]
Walsh, Patrick C. [1 ]
机构
[1] Johns Hopkins Sch Med, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA
关键词
D O I
10.1016/j.urology.2007.10.053
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The new American Society for Therapeutic Radiology and Oncology/Radiation Therapy Oncology Group consensus definition of biochemical failure after radiotherapy for prostate cancer is defined as a prostate-specific antigen level at or greater than the absolute nadir PSA level plus 2 ng/mL. Bccause this definition inevitably will be used to compare cancer control rates after radiotherapy to those after Surgery, this study examined the effect of this comparison. METHODS We reviewed the data from 2570 men who had undergone radical prostatectomy from 1985 to 2004. Biochemical failure was defined as any measurable PSA level Of 0.2 ng/mL or greater. We evaluated how the nadir+2 definition affected the failure rate when applied to this series. RESULTS The actuarial 5, 10, and 15-year biochemical recurrence-free survival probability with failure defined as a PSA level of 0.2 ng/mL or more and a PSA level of 2 ng/mL or more was 88.6% 81.2%, and 78.1% and 94.6%, 89.4%, and 84.3%), respectively (P < 0.0001). The median time to biochemical progression was 2.8 years for the greater than 0.2 ng/mL definition and 7.9 years for the 2 ng/mL or more definition. The nadir+2 definition systematically overestimated the biochemical recurrence-free survival, even after stratifying patients into standard prognostic risk groups, especially in men who developed local recurrence. CONCLUSIONS When applied to a mature series of surgically treated patients with localized prostate cancer, the American Society for Therapeutic Radiology and Oncology "nadir+2" definition resulted in a systematic delay in the determination of biochemical failure. Because patients in this series who experienced a detectable PSA level took more than 5 years to progress to a PSA level of 2 ng/mL or greater, the 5-year biochemical control rates with the definition of 0.2 ng/mL or more should be compared with the 10-year biochemical control rates using the nadir+2 definition.
引用
收藏
页码:389 / 393
页数:5
相关论文
共 24 条
[1]   Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point? [J].
Amling, CL ;
Bergstralh, EJ ;
Blute, ML ;
Slezak, JM ;
Zincke, H .
JOURNAL OF UROLOGY, 2001, 165 (04) :1146-1151
[2]   Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer update panel report and recommendations for a standard in the reporting of surgical outcomes [J].
Cookson, Michael S. ;
Aus, Gunnar ;
Burnett, Arthur L. ;
Canby-Hagino, Edith D. ;
D'Amico, Anthony V. ;
Dmochowski, Roger R. ;
Eton, David T. ;
Forman, Jeffrey D. ;
Goldenberg, S. Larry ;
Hernandez, Javier ;
Higano, Celestia S. ;
Kraus, Stephen R. ;
Moul, Judd W. ;
Tangen, Catherine ;
Thrasher, J. Brantley ;
Thompson, Ian .
JOURNAL OF UROLOGY, 2007, 177 (02) :540-545
[3]  
Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035
[4]   A standard definition of disease freedom is needed for prostate cancer: Undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology Consensus Definition [J].
Critz, FA .
JOURNAL OF UROLOGY, 2002, 167 (03) :1310-1313
[5]   The PSA nadir that indicates potential cure after radiotherapy for prostate cancer - Editorial comment [J].
Klein, EA ;
Kupelian, PJ .
UROLOGY, 1997, 49 (03) :326-326
[6]   Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Cote, K ;
Loffredo, M ;
Schultz, D ;
Chen, MH ;
Tomaszewski, JE ;
Renshaw, AA ;
Wein, A ;
Richie, JP .
CANCER, 2002, 95 (02) :281-286
[7]   Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Schultz, D ;
Blank, K ;
Broderick, GA ;
Tomaszewski, JE ;
Renshaw, AA ;
Kaplan, I ;
Beard, CJ ;
Wein, A .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :969-974
[8]   Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era [J].
D'Amico, AV ;
Whittington, R ;
Malkowicz, SB ;
Weinstein, M ;
Tomaszewski, JE ;
Schultz, D ;
Rhude, M ;
Rocha, S ;
Wein, A ;
Richie, JP .
JOURNAL OF UROLOGY, 2001, 166 (06) :2185-2188
[9]   Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy [J].
Freedland, SJ ;
Sutter, ME ;
Dorey, F ;
Aronson, WJ .
UROLOGY, 2003, 61 (02) :365-369
[10]   A critical analysis of the interpretation of biochemical failure in surgically treated patients using the american society for therapeutic radiation and oncology criteria [J].
Gretzer, MB ;
Trock, BJ ;
Han, M ;
Walsh, PC .
JOURNAL OF UROLOGY, 2002, 168 (04) :1419-1422